Invasive pulmonary aspergillosis secondary to microwave ablation: a multicenter retrospective study

Huang, Guanghui; Ye, Xin; Yang, Xia; Wang, Chuntang; Zhang, Licheng; Ji, Guangdong; Zhang, Kaixian; Wang, Huili; Zheng, Ai; Li, Wenhong; Wang, Jiao; Han, Xiaoying; Wei, Zhigang; Meng, Min; Ni, Yang

doi:10.1080/02656736.2018.1476738

Cited by 14 publications

(8 citation statements)

References 35 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumonia (4.5%) could be effectively cured by appropriate antibiotics as previously reported [19,35]. There was no reported case of life-threatening invasive aspergillosis [36,37]. Nerve injury of brachial plexus (1.5%) has been rarely reported and the symptoms partially receded over time [38].…”

Section: Discussionmentioning

confidence: 54%

A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: a novel therapy for multiple synchronous ground-glass opacities of the lung

Huang

Yang

et al. 2020

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 54%

A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: a novel therapy for multiple synchronous ground-glass opacities of the lung

Huang

Yang

et al. 2020

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

show abstract

“…The incidence of pleural effusions requiring drainage in the current study is in accordance with that reported in previous studies, and the incidence of Aspergillus infection in the current study is consistent with that reported by Huang et al . (1.44%) …”

Section: Discussionmentioning

confidence: 98%

“…33 The incidence of pleural effusions requiring drainage in the current study is in accordance with that reported in previous studies, 20,33 and the incidence of Aspergillus infection in the current study is consistent with that reported by Huang et al (1.44%). 34 This study had several limitations: (i) it used a small sample size; (ii) it was retrospective in nature; (iii) data on factors that could influence outcomes were unavailable; and (iv) multiple devices were used by multiple operators.…”

Section: Discussionmentioning

confidence: 99%

Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundPrevious studies have documented the therapeutic value of computed tomography (CT)‐guided percutaneous microwave ablation (MWA) for early‐stage non‐small cell lung cancer (NSCLC). However, few studies have focused on patients aged 80 years and older. This retrospective study aimed to evaluate the safety and clinical outcomes of CT‐guided percutaneous MWA in patients aged 80 years and older with early‐stage peripheral NSCLC.MethodsA retrospective analysis of 63 patients aged 80 years and older with cT1a‐2bN0M0 peripheral NSCLC who underwent CT‐guided percutaneous MWA was performed between January 2008 and January 2018 at 11 hospitals in Shandong Province, China.ResultsThe median follow‐up time was 21.0 months. The overall median survival time was 50 months. The cancer‐specific median survival time was not reached in five years. The one‐, two‐, three‐, four‐, and five‐year overall survival rates were 97.1%, 92.6%, 63.4%, 54.4%, and 32.6%, respectively. The one‐, two‐, and three‐year cancer‐specific survival (CSS) rates were 97.9%, 97.9%, and 69.4%, respectively. The four‐ and five‐year CSS rates were not achieved. A total of 14 patients (22.2%) had local progression. The one‐, two‐, three‐, four‐, and five‐year local control rates were 88.8%, 78.8%, 70.3%, 63.9%, and 63.9%, respectively. The mortality rate was 0% within 30 days after the procedure. Major complications included pneumothorax requiring drainage (21.1%), pulmonary infection (4.2%), and pleural effusions requiring drainage (2.8%).ConclusionsCT‐guided percutaneous MWA is a safe and effective modality for treating patients aged 80 years and older with early‐stage peripheral NSCLC.

show abstract

“…In a cohort of 1,596 patients, 23 developed an IA after microwave therapy. 86 The patients with IA were more likely to be male and to have COPD, history of smoking, and primary lung tumor.…”

Section: Solid Tumorsmentioning

confidence: 99%

Invasive Pulmonary Aspergillosis

Ledoux

Guffroy

Nivoix

et al. 2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Invasive pulmonary aspergillosis (IPA) remains difficult to diagnose and to treat. Most common risk factors are prolonged neutropenia, hematopoietic stem cell or solid organ transplantation, inherited or acquired immunodeficiency, administration of steroids or other immunosuppressive agents including monoclonal antibodies and new small molecules used for cancer therapy. Critically ill patients are also at high risk of IPA. Clinical signs are unspecific. Early computed tomography (CT)-scan identifies the two main aspects, angioinvasive and airway invasive aspergillosis. Although CT-scan findings are not fully specific they usually allow early initiation of therapy before mycological confirmation of the diagnosis. Role of 18F-fludeoxyglucose positron emission tomography with computed tomography (18F-FDG PET/CT) is discussed. Confirmation is based on microscopy and culture of respiratory samples, histopathology in case of biopsy, and importantly by detection of Aspergillus galactomannan using an immunoassay in serum and bronchoalveolar lavage fluid. Deoxyribonucleic acid detection by polymerase chain reaction is now standardized and increases the diagnosis yield. Two point of care tests detecting an Aspergillus glycoprotein using a lateral flow assay are also available. Mycological results allow classification into proven (irrespective of underlying condition), probable or possible (for cancer and severely immunosuppressed patients) or putative (for critically ill patients) IPA. New antifungal agents have been developed over the last 2 decades: new azoles (voriconazole, posaconazole, isavuconazole), lipid formulations of amphotericin B (liposomal amphotericin B, amphotericin B lipid complex), echinocandins (caspofungin, micafungin, anidulafungin). Results of main trials assessing these agents in monotherapy or in combination are presented as well as the recommendations for their use according to international guidelines. New agents are under development.

show abstract

Invasive pulmonary aspergillosis secondary to microwave ablation: a multicenter retrospective study

Cited by 14 publications

References 35 publications

A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: a novel therapy for multiple synchronous ground-glass opacities of the lung

A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: a novel therapy for multiple synchronous ground-glass opacities of the lung

Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study

Invasive Pulmonary Aspergillosis

Contact Info

Product

Resources

About